Aikaterini Masgala

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Evdoxia Kyriazopoulou, Haralampos Milionis, Symeon Metallidis et al. · Nature Medicine · 2021 · 518 citations · Full text

Ceftazidime/avibactam in the era of carbapenemase-producing <i>Klebsiella pneumoniae</i>: experience from a national registry study

Ilias Karaiskos, George L. Daikos, Aikaterini Gkoufa et al. · Journal of Antimicrobial Chemotherapy · 2020 · 97 citations

Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae

Maria Souli, Ilias Karaiskos, Aikaterini Masgala et al. · European Journal of Clinical Microbiology & Infectious Diseases · 2017 · 59 citations

Untreatable Infections, Health Sciences, Antibiotics +13

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

Evangelos J. Giamarellos‐Bourboulis, Athanasios Siampanos, Amalia Bolanou et al. · The Lancet Respiratory Medicine · 2024 · 51 citations

Community-acquired Pneumonia, Antibiotics, Antimicrobial Stewardship +7

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial

Karolina Akinosoglou, Antigone Kotsaki, Maria Ioanna Gounaridi et al. · EClinicalMedicine · 2022 · 22 citations · Full text